Campbell DJ, et al. - In a community-based population at increased risk for cardiovascular disease (CVD), researchers investigated serum amino-terminal pro-B-type-natriuretic peptide (NT-proBNP) levels that inform heart failure (HF) risk. Adults aged ≥ 60 years with one or more of self-reported health conditions of hypertension, diabetes, heart disease, abnormal heart rhythm, cerebrovascular disease, or renal impairment were included; those with known HF, ejection fraction (EF) < 50%, or more than mild valve abnormality were excluded. With sensitivities > 76% and specificities of 47% to 69%, 5-year prediction of total HF was achieved with NT-proBNP cut-points of 11, 16, and 25 pmol/L for individuals aged 60–69, 70–79, and ≥ 80 years, respectively, in men and women in all three age groups. Sensitivities were ≥ 75% in most subgroups according to BMI, eGFR, and the presence or absence of atrial fibrillation, pacemaker, or CVD, and for the prediction of HF with preserved EF (HFpEF), HF with reduced EF (HFrEF), and valvular HF (VHF). Overall, prognosis as well as therapeutic decisions regarding HF risk were informed by age-specific serum NT-proBNP levels in individuals at increased CVD risk.